FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089649437> ?p ?o ?g. }

• W2089649437 endingPage "583" @default.
• W2089649437 startingPage "579" @default.
• W2089649437 abstract "Monotherapy has tended to replace the combination therapy in emprical treatment of febrile neutropenia. There is no reported trial which compares the efficacy of cefoperazone-sulbactam (CS) and piperacillin-tazobactam (PIP/TAZO) monotherapies in the treatment of febrile neutropenia. In this prospective randomized study, we aimed to compare the safety and efficacy of CS versus PIP/TAZO as empirical monotherapies in febrile neutropenic children with cancer.The study included febrile, neutropenic children hospitalized at our center for cancer. They were randomly selected to receive CS 100 mg/kg/day or PIP/TAZO 360 mg/kg/day. Duration of fever and neutropenia, absolute neutrophil count, modification, and success rate were compared between the two groups. Resolution of fever without antibiotic change was defined as success and resolution of fever with antibiotic change or death of a patient was defined as failure. Modification was defined as changing the empirical antimicrobial agent during a febrile episode.One hundred and two febrile neutropenic episodes were documented in 55 patients with a median age of 4 years. In 50 episodes CS and in 52 episodes PIP/TAZO was used. Duration of fever and neutropenia, neutrophil count, age, sex, and primary disease were not different between two groups. Success rates in the CS and PIP/TAZO groups were respectively 56 and 62% (P > 0.05). Modification rate between two groups showed no significant difference (P > 0.05). No serious adverse effect occurred in either of the groups.CS and PIP/TAZO monotherapy are both safe and effective in the initial treatment of febrile neutropenia in children with cancer." @default.
• W2089649437 created "2016-06-24" @default.
• W2089649437 creator A5002176677 @default.
• W2089649437 creator A5008028706 @default.
• W2089649437 creator A5009190813 @default.
• W2089649437 creator A5020511059 @default.
• W2089649437 creator A5035221088 @default.
• W2089649437 creator A5091216647 @default.
• W2089649437 date "2011-06-14" @default.
• W2089649437 modified "2023-10-18" @default.
• W2089649437 title "Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia" @default.
• W2089649437 cites W1829418230 @default.
• W2089649437 cites W1932756735 @default.
• W2089649437 cites W1977969872 @default.
• W2089649437 cites W1982667310 @default.
• W2089649437 cites W1982893210 @default.
• W2089649437 cites W1985549263 @default.
• W2089649437 cites W2004600223 @default.
• W2089649437 cites W2026519975 @default.
• W2089649437 cites W2032951174 @default.
• W2089649437 cites W2060490442 @default.
• W2089649437 cites W2061194988 @default.
• W2089649437 cites W2067724073 @default.
• W2089649437 cites W2068817926 @default.
• W2089649437 cites W2073089671 @default.
• W2089649437 cites W2073912062 @default.
• W2089649437 cites W2086629824 @default.
• W2089649437 cites W2093837107 @default.
• W2089649437 cites W2097070667 @default.
• W2089649437 cites W2103960766 @default.
• W2089649437 cites W2108818954 @default.
• W2089649437 cites W2120390073 @default.
• W2089649437 cites W2122335736 @default.
• W2089649437 cites W2124888195 @default.
• W2089649437 cites W2126620965 @default.
• W2089649437 cites W2128894959 @default.
• W2089649437 cites W2151422047 @default.
• W2089649437 cites W2161554499 @default.
• W2089649437 cites W2166858780 @default.
• W2089649437 cites W2166895354 @default.
• W2089649437 cites W2225659496 @default.
• W2089649437 cites W2335721167 @default.
• W2089649437 cites W4237334640 @default.
• W2089649437 doi "https://doi.org/10.1002/pbc.23245" @default.
• W2089649437 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21674768" @default.
• W2089649437 hasPublicationYear "2011" @default.
• W2089649437 type Work @default.
• W2089649437 sameAs 2089649437 @default.
• W2089649437 citedByCount "17" @default.
• W2089649437 countsByYear W20896494372012 @default.
• W2089649437 countsByYear W20896494372013 @default.
• W2089649437 countsByYear W20896494372014 @default.
• W2089649437 countsByYear W20896494372016 @default.
• W2089649437 countsByYear W20896494372017 @default.
• W2089649437 countsByYear W20896494372018 @default.
• W2089649437 countsByYear W20896494372020 @default.
• W2089649437 countsByYear W20896494372021 @default.
• W2089649437 countsByYear W20896494372022 @default.
• W2089649437 countsByYear W20896494372023 @default.
• W2089649437 crossrefType "journal-article" @default.
• W2089649437 hasAuthorship W2089649437A5002176677 @default.
• W2089649437 hasAuthorship W2089649437A5008028706 @default.
• W2089649437 hasAuthorship W2089649437A5009190813 @default.
• W2089649437 hasAuthorship W2089649437A5020511059 @default.
• W2089649437 hasAuthorship W2089649437A5035221088 @default.
• W2089649437 hasAuthorship W2089649437A5091216647 @default.
• W2089649437 hasConcept C126322002 @default.
• W2089649437 hasConcept C197934379 @default.
• W2089649437 hasConcept C2776694085 @default.
• W2089649437 hasConcept C2776999253 @default.
• W2089649437 hasConcept C2777063308 @default.
• W2089649437 hasConcept C2777637488 @default.
• W2089649437 hasConcept C2777858937 @default.
• W2089649437 hasConcept C2778193466 @default.
• W2089649437 hasConcept C2778266534 @default.
• W2089649437 hasConcept C2778850193 @default.
• W2089649437 hasConcept C2779631663 @default.
• W2089649437 hasConcept C501593827 @default.
• W2089649437 hasConcept C523546767 @default.
• W2089649437 hasConcept C54355233 @default.
• W2089649437 hasConcept C71924100 @default.
• W2089649437 hasConcept C74133956 @default.
• W2089649437 hasConcept C86803240 @default.
• W2089649437 hasConcept C89423630 @default.
• W2089649437 hasConcept C94665300 @default.
• W2089649437 hasConceptScore W2089649437C126322002 @default.
• W2089649437 hasConceptScore W2089649437C197934379 @default.
• W2089649437 hasConceptScore W2089649437C2776694085 @default.
• W2089649437 hasConceptScore W2089649437C2776999253 @default.
• W2089649437 hasConceptScore W2089649437C2777063308 @default.
• W2089649437 hasConceptScore W2089649437C2777637488 @default.
• W2089649437 hasConceptScore W2089649437C2777858937 @default.
• W2089649437 hasConceptScore W2089649437C2778193466 @default.
• W2089649437 hasConceptScore W2089649437C2778266534 @default.
• W2089649437 hasConceptScore W2089649437C2778850193 @default.
• W2089649437 hasConceptScore W2089649437C2779631663 @default.
• W2089649437 hasConceptScore W2089649437C501593827 @default.
• W2089649437 hasConceptScore W2089649437C523546767 @default.

• next